Stockreport

Sagimet Biosciences Advances Denifanstat: Q3 Earnings And Upcoming Catalysts [Seeking Alpha]

Sagimet Biosciences Inc. - Series A  (SGMT) 
PDF SGMT's cash position remains robust at $125.5 million, supporting clinical milestones into 2026 despite ongoing R&D-driven losses and disciplined operating spend. Den [Read more]